LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System.

NCT ID: NCT04790344

Last Updated: 2025-11-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

525 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-20

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to collect sensor data from insertable cardiac monitor systems.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of this study is to collect physiological measurement data and heart failure (HF) event data that will be used to design and develop new diagnostic features for the insertable cardiac monitor (ICM) systems. This study will not have pre-defined statistical endpoints. To support the primary objective, diagnostic sensor data will be compared to reference clinical testing data and heart failure decompensation events.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Physiologic Sensor data will be blinded to participants and care providers. LUX-Dx ICM commercial features will be Open Label.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Arm

All study subjects belong to Treatment Arm, which is receiving investigational LUX-Dx ICM device.

Group Type EXPERIMENTAL

Investigational LUX-Dx ICM Implant

Intervention Type DEVICE

All subject will receive an investigational version of the LUX-Dx ICM device.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Investigational LUX-Dx ICM Implant

All subject will receive an investigational version of the LUX-Dx ICM device.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient is currently in NYHA Class II or III.
* For patients with LVEF \>40% measured on most recent available echocardiography within the previous 12 months:

* ONE (1) of the following echocardiography findings: LA width (diameter) \>3.8 cm, LA length \>5.0 cm, LA area \>20 cm2, LA volume \>55 ml, LA volume index \>29 ml/m2, LVH defined by septal thickness or posterior wall thickness of \>1.1 cm AND
* ONE (1) of the following: Elevated BNP/NT-proBNP as defined by: BNP \>100 pg/ml or NT-proBNP \>300 pg/ml within the previous 90 days for patients not in atrial fibrillation or BNP \>300 pg/ml or NT-proBNP \>900 pg/ml for patients in atrial fibrillation at the time of screening for eligibility OR Documented heart failure hospitalization or unscheduled heart failure IV therapy in the previous 12 months
* For patients with LVEF \<40% (for MI patients, measured no less than 30 days post-MI) on most recent available echocardiography within the previous 12 months:

* ONE (1) of the following: Elevated BNP/NT-proBNP as defined by BNP \>150 pg/ml or NT-proBNP \>600 pg/ml within the previous 90 days for patients not in atrial fibrillation or BNP \>450 pg/ml or NT-proBNP \>1800 pg/ml for patients in atrial fibrillation at the time of screening for eligibility OR Documented heart failure hospitalization or unscheduled heart failure IV therapy in the previous 12 months
* Patient is willing to be monitored in LATITUDE Clarity and use the ICM patient mobile app.
* Patient is of legal age to give informed consent and is willing to participate in the trial.

Exclusion Criteria

* Patient is currently implanted with any other active electronic medical device.
* Patient has undergone a heart transplant.
* Patient is currently enrolled in another investigational study (excluding registries) without prior written approval from Boston Scientific.
* Patient is known to be pregnant at the time of enrollment or plans to become pregnant during study participation.
* Patient is diagnosed with amyloidosis or hypertrophic cardiomyopathy.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boston Scientific Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Scott Solomon, MD

Role: PRINCIPAL_INVESTIGATOR

Brigham and Women's Hospital

Elaine Wan, MD

Role: PRINCIPAL_INVESTIGATOR

Columbia University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Grandview Medical Center - Affinity Hospital, LLC

Birmingham, Alabama, United States

Site Status

Mobile Infirmary

Mobile, Alabama, United States

Site Status

Arrhythmia Research Group

Jonesboro, Arkansas, United States

Site Status

John Muir Medical Center

Concord, California, United States

Site Status

Scripps Memorial Hospital

La Jolla, California, United States

Site Status

VA Loma Linda

Loma Linda, California, United States

Site Status

Kaiser Permanenty Los Angeles Medical Center

Los Angeles, California, United States

Site Status

University of California - Irvine

Orange, California, United States

Site Status

San Diego Cardiac Center

San Diego, California, United States

Site Status

Cardiology Associates Medical Group

Ventura, California, United States

Site Status

The Cardiac and Vascular Institute

Gainesville, Florida, United States

Site Status

North Florida South Georgia VA

Gainesville, Florida, United States

Site Status

St. John's Center for Clinical Research (First Coast Heart and Vascular Center, PLLC)

Jacksonville, Florida, United States

Site Status

Village Heart and Vein Center

Lady Lake, Florida, United States

Site Status

Naples Heart and Rhythm

Naples, Florida, United States

Site Status

Sarasota Memorial Hospital

Sarasota, Florida, United States

Site Status

Piedmont Augusta Hospital

Augusta, Georgia, United States

Site Status

Augusta University

Augusta, Georgia, United States

Site Status

Northside Hospital

Gainesville, Georgia, United States

Site Status

Northeast Georgia Heart Center, Inc.

Gainesville, Georgia, United States

Site Status

St. Luke's Idaho Cardiology Associates

Boise, Idaho, United States

Site Status

Northwestern University

Chicago, Illinois, United States

Site Status

Advocate Good Samaritan Hospital

Downers Grove, Illinois, United States

Site Status

Franciscan Physician Network-Indiana Heart Physicians

Indianapolis, Indiana, United States

Site Status

Community Heart and Vascular Hospital

Indianapolis, Indiana, United States

Site Status

University of Kansas Hospital

Kansas City, Kansas, United States

Site Status

Baptist Health Lexington

Lexington, Kentucky, United States

Site Status

M Health Fairview St. John's Hospital

Maplewood, Minnesota, United States

Site Status

Minneapolis VA

Minneapolis, Minnesota, United States

Site Status

University of Mississippi Medical Center

Jackson, Mississippi, United States

Site Status

Cardiology Associates Research, LLC/North Mississippi Medical Center

Tupelo, Mississippi, United States

Site Status

Saint Luke's Hospital of Kansas City

Kansas City, Missouri, United States

Site Status

Saint Louis University Hospital

St Louis, Missouri, United States

Site Status

Cardiovascular Associates of the Delaware Valley

Sewell, New Jersey, United States

Site Status

Capital Cardiology Associates, PC

Albany, New York, United States

Site Status

New York Methodist Hospital

Brooklyn, New York, United States

Site Status

Columbia University Medical Center/NYPH

New York, New York, United States

Site Status

The New York Hospital Medical Center of Queens

New York, New York, United States

Site Status

Sanger Heart and Vascular Institute

Charlotte, North Carolina, United States

Site Status

Medication Management

Greensboro, North Carolina, United States

Site Status

WakeMed

Raleigh, North Carolina, United States

Site Status

Wake Forest University School of Medicine

Winston-Salem, North Carolina, United States

Site Status

Sacred Heart Medical Center at Riverbend

Springfield, Oregon, United States

Site Status

Lehigh Valley Hospital

Allentown, Pennsylvania, United States

Site Status

Penn State Health Milton S. Hershey Medical Center

Hershey, Pennsylvania, United States

Site Status

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, United States

Site Status

University of Pittsburgh Medical Center Presbyterian Hospital

Pittsburgh, Pennsylvania, United States

Site Status

Wellspan York Hospital

York, Pennsylvania, United States

Site Status

Ralph H. Johnson Department of Veterans Affairs Medical Center

Charleston, South Carolina, United States

Site Status

St. Thomas Research Institute

Nashville, Tennessee, United States

Site Status

Cardiovascular Research of Knoxville

Powell, Tennessee, United States

Site Status

University of Texas Medical Branch

Galveston, Texas, United States

Site Status

Orion Medical

Pasadena, Texas, United States

Site Status

VA Puget Sound Healthcare System

Seattle, Washington, United States

Site Status

PeaceHealth Southwest

Vancouver, Washington, United States

Site Status

Marshall Cardiology

Huntington, West Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

C2118

Identifier Type: -

Identifier Source: org_study_id